Brain cells tied to REM sleep cycle, affected in Parkinson’s, identified
A specific population of nerve cells in the brain that helps to regulate REM sleep may be a key target…
Articles by Marisa Wexler, MS
AbbVie levodopa therapy approved as Vyalev for advanced Parkinson’s
The U.S. Food and Drug Administration (FDA) has approved foslevodopa and foscarbidopa, a levodopa therapy given as a 24-hour under-the-skin…
AAV-GAD gene therapy eases Parkinson’s symptoms in early study
Treatment with the experimental gene therapy AAV-GAD led to significant easing of motor symptoms and improved life quality for…
Machine-learning analysis of videos may help identify Parkinson’s
Conducting a machine-learning analysis of video recordings may aid in identifying motor symptoms in the early stage of Parkinson’s…
Mutations in ITSN1 gene linked with higher risk of Parkinson’s
Mutations that inactivate a gene called ITSN1 are associated with an increased risk of Parkinson’s disease, particularly at younger…
Dementia not a given in decade after Parkinson’s diagnosis: Study
Most people with Parkinson’s disease don’t experience dementia in the first decade after diagnosis, a study reported. The…
Cell model recreates dynamics of alpha-synuclein clumping: Study
A new cell model of Parkinson’s disease is better able than others at capturing the complexity of the toxic…
FDA approves extended-release levodopa/carbidopa, now Crexont
Note: This article was updated Aug. 9, 2024, to correct that the improvement seen in good on time in additional…
Parkinson’s mutations seen in nearly 13% of PD GENEration patients
Nearly 13% of people with Parkinson’s disease in North America carry a Parkinson’s-associated genetic mutation, according to new data…
Targeting healthy alpha-synuclein may limit its toxic spread in brain
Lowering the levels of healthy alpha-synuclein, which is naturally found in the brain, helped to suppress the spread of this…